Physician profile
Yan Meng
NPI 1770661274
$7,912.47
in general payments reported to CMS, 2019-2025
33 companies · $1,652 in 2025
The $1,652 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,626 · 2020: $351 · 2021: $1,102 · 2022: $671 · 2023: $602 · 2024: $909 · 2025: $1,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,145 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,144.99 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,411.53 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,001.23 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $669.59 | 2019-2025 | Tezspire, Lumakras |
| Regeneron Healthcare Solutions, INC. | $647.72 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.85 | 2019-2025 | Jascayd |
| Genzyme Corporation | $407.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $349.58 | 2019-2023 | Xarelto |
| Genentech USA, INC. | $328.39 | 2019 | |
| Lilly USA, LLC | $289.58 | 2019-2023 | |
| Daiichi Sankyo INC. | $215.75 | 2021 | |
| Janssen Biotech, INC. | $215.51 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $195.28 | 2019 | |
| Merck Sharp & Dohme LLC | $178.31 | 2019-2023 | Keytruda |
| Gilead Sciences, INC. | $141.30 | 2019-2024 | Vemlidy |
| Incyte Corporation | $125.00 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.16 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $118.13 | 2019 | |
| Verona Pharma, INC. | $106.66 | 2025 | Ohtuvayre |
| Tesaro, INC. | $104.63 | 2019 | |
| Kite Pharma, INC. | $100.90 | 2019 | |
| Insmed, INC. | $100.40 | 2022-2025 | Brinsupri, Arikayce |
| Novartis Pharmaceuticals Corporation | $91.80 | 2019 | |
| Eisai INC. | $88.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $85.30 | 2023 | Opdivo |
| Baxter Healthcare | $75.93 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Advanced Accelerator Applications | $56.99 | 2019 | |
| Viatris Specialty LLC | $51.00 | 2025 | Yupelri |
| Circassia INC. | $46.20 | 2019-2020 | |
| Grifols USA, LLC | $33.08 | 2025 | Prolastin-C Liquid |
| Philips North America LLC | $28.55 | 2019-2020 | |
| Mylan Specialty L.P. | $26.94 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $22.75 | 2023 | Inspire |
| Csl Behring | $22.44 | 2024 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Meng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.